Stock CARM CARISMA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
1.87 USD +14.72% Intraday chart for Carisma Therapeutics, Inc. +6.25% -36.18%
Apr. 11 BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target MT
Apr. 02 HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target
MT
Carisma Therapeutics to Present at Upcoming Conferences
PR
HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating
MT
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Carisma Therapeutics Q4 Net Loss Narrows, Revenue Rises; Plans Job Cuts in Q2 -- Shares Decline
MT
Carisma Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Carisma Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Carisma Therapeutics Announces Changes to its Board of Directors
PR
Carisma Therapeutics, Inc. Announces Changes to Its Board of Directors
CI
North American Morning Briefing : Stock Futures -2-
DJ
North American Morning Briefing : Inflation Data -2-
DJ
Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference
PR
Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Carisma Therapeutics' First Lead Candidate Under Moderna Deal to Target Cancer Treatment
MT
Carisma Therapeutics Obtains FDA Clearance to Study Potential Solid Tumor Therapy
MT
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
PR
Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte
CI
Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference
PR
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
North American Morning Briefing : Stocks Look to -2-
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CARM Stock
  4. News Carisma Therapeutics, Inc.